SCHEMBL9456

SCHEMBL9456

CCCC(CC1CCCCC1)C(=O)NC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.43
LTA4H P09960 1/20 0.43
METAP2 P50579 2/20 0.42
HDAC7 Q8WUI4 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
CTSK P43235 3/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
REN P00797 1/20 0.39
MMP1 P03956 3/20 0.38
MMP13 P45452 1/20 0.38
MMP3 P08254 1/20 0.38
LONP1 P36776 1/20 0.37
ATM Q13315 1/20 0.36
CTSS P25774 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13500182 0.98 ALDH1A1 (0.47) ALDH1A1KMT2ASMN1; SMN2LTA4HMETAP2
SCHEMBL13501740 0.95 ALDH1A1 (0.44) ALDH1A1KMT2ASMN1; SMN2LTA4HMETAP2
SCHEMBL13500239 0.91 HDAC7 (0.44) ALDH1A1KMT2ASMN1; SMN2LTA4HMETAP2
SCHEMBL13500202 0.89 ALDH1A1 (0.51) ALDH1A1KMT2ALTA4HMETAP2CTSK
SCHEMBL8288403 0.87 ALDH1A1 (0.43) ALDH1A1KMT2ALTA4HMETAP2CTSK
SCHEMBL13500204 0.85 ALDH1A1 (0.48) ALDH1A1KMT2AMETAP2CTSKCTSL
SCHEMBL13500299 0.85 ALDH1A1 (0.41) ALDH1A1KMT2ALTA4HMETAP2CTSK
SCHEMBL13500292 0.83 ALDH1A1 (0.40) ALDH1A1KMT2ALTA4HMETAP2CTSK
SCHEMBL13499659 0.83 LTA4H (0.49) ALDH1A1KMT2ASMN1; SMN2LTA4HMETAP2
SCHEMBL13461525 0.83 ALDH1A1 (0.46) ALDH1A1KMT2ASMN1; SMN2LTA4HMETAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296698-B2 Amino heteroaryl compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2016-03-29 US disclosed
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use AMGEN INC. (US) 2012-12-27 US disclosed
EP-2504315-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2012-10-03 EP disclosed
WO-2011063233-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use BACE1, BACE2, APP ALDH1A1 1846/4885KMT2A 1441/4885SMN1; SMN2 3569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.